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Introduction
In previous work we argued that sociologists need to expand our thinking about
pharmaceuticalization, the process of understanding and/or treating social, behavioral, or
bodily conditions with pharmaceuticals. The majority of sociological scholarship has
investigated pharmaceuticalization as a primarily Western process and conceptualized it
in modern terms (Bell and Figert 2010, 2012a, 2012b). In our view, the work of
anthropologists and science and technology studies (STS) scholars who decenter the
West as the starting point for research opens up new avenues for understanding the global
dynamics of pharmaceuticalization. We have also argued in favor of adopting a
postmodern theoretical lens which allows us to understand pharmaceuticalization both as
a strategy of enhancement by individuals in resource-rich societies and as an exercise of
power in resource-poor societies and to bring to light its multiple, multidirectional and at
times apparently contradictory effects.
In this chapter we expand upon our previous work and focus on one essential part
of the pharmaceuticalization process: global clinical trials and related ethical and research
standards. We also consider the role of global clinical trials in reducing public health
strategies from a broad array of disease prevention efforts to one seeking to improve the
health of populations with pharmaceuticals. The issues we explore center upon the key
research and ethical standards for global pharmaceutical development. We define, review
and problematize the concept of ethical variability and show how it simultaneously
upholds and disrupts Western ethical guidelines for human subjects research. In doing so,
we show how global clinical trials contribute to the further pharmaceuticalization of
public health worldwide with major implications for people’s lives globally. The degree
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and scope of how people interact with pharmaceuticals throughout the world is uneven,
because pharmaceuticalization and global clinical trials map onto global patterns of
inequality. Some human bodies serve as research subjects whereas some bodies are
pharmaceutical sales targets. Whereas some people in some areas of the world are
(over)pharmaceuticalized, other people are (under)pharmaceuticalized. We conclude the
chapter with a discussion of how and why STS perspectives on harmonization and
variability in ethical and research standards shed light on the study of
pharmaceuticalization and more broadly on the global dynamics of health inequality.

Conceptual Framing: Medicalization, Biomedicalization and Pharmaceuticalization
Because studies of pharmaceuticalization have taken shape alongside the
development of scholarship about medicalization and biomedicalization, we begin with a
brief overview of these fields. The concept of medicalization was introduced to the
medical sociology field in the 1970s to understand and look critically at “the involvement
of medicine in the management of society” (Zola 1972: 488). Medicalization is now
ubiquitously used in the social and medical sciences and has successfully moved into
popular culture. One of the most influential definitions of medicalization comes from US
sociologist Peter Conrad (2005:3) who declares that the essential meaning of the term is
“defining a problem in medical terms, usually as an illness or disorder, or using a
medical intervention to treat it” [emphasis in the original]. Medicalization explains a
process of medical expansion in a modern society. It makes sense of how and why more
and more conditions are defined and treated medically and increasingly pharmaceutically.
Current medicalization scholarship has refocused our analytic gaze from the
power and authority of the medical profession to consider the active participation of
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individual patient/consumer/users individually and collectively in medicalization
processes (Brown and Zavestoski 2005; Crossley 2006), resistance to pharmaceuticals
(Figert 2011; Williams et al. 2011), and the use of medical prescription drugs for
nonmedical purposes (Williams, Seale et al. 2008). It has also explored new “engines” of
medicalization including the pharmaceutical industry (Conrad 2005) and technoscience
(Clarke et al. 2003). Although medicalization is a capacious concept, it cannot fully
capture the contemporary global dynamics of pharmaceuticals and technoscience. Thus
scholars have introduced the concepts of biomedicalization, pharmaceuticalization, and
pharmaceuticalization of public health, which are often more effective than
medicalization alone in analyzing the nuances and complexities of the development,
testing, expansion and distribution of pharmaceuticals in the world today (see Abraham
and Davis (2014) in this volume and Bell and Figert 2012a for a more extensive
discussion).
Whereas the process of medicalization can be conceived of in modern terms of
engineering, control, and rationalization, the process of biomedicalization can be
conceived of in postmodern terms of networks, spirals, and complexity. Understanding
both the definition and effects of biomedicalization helps to make sense of how and why
more and more conditions are defined and treated medically and pharmaceutically in the
21st century. Biomedicalization, as established by Clarke and her colleagues, is a concept
and analytic tool that captures “the increasingly complex, multisited, multidirectional
processes of medicalization that today are being both extended and reconstituted through
the emergent social forms and practices of a highly and increasingly technoscientific
biomedicine” (Clarke et al 2003, 162). One example of this is the application of screening
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technologies using molecular biomarkers that constitute new categories of people at risk
and new opportunities for biomedical surveillance and intervention as well as selfmonitoring and regimens of behavior change (Shostak 2010).
Although feminist scholars and activists in Women’s Health Movements have
looked critically at the development of the birth control pill and other reproductive
technologies since the 1970s and social scientists have studied pharmaceuticals and the
pharmaceutical industry for many years (e.g., Boston Women’s Health Book Collective
1973; Hartmann 1987; Gabe and Bury 1988), pharmaceuticalization as a unique term was
introduced by anthropologists (Nichter 1989). A broadly accepted definition of
pharmaceuticalization by sociologist John Abraham is “the process by which social,
behavioral or bodily conditions are treated, or deemed to be in need of
treatment/intervention, with pharmaceuticals by doctors, patients, or both” (Abraham
2010a: 290). There are complex forces generating the expansion of
pharmaceuticalization: Big Pharma’s industry control over the science underpinning drug
development and testing, skillful use of marketing, and “disease mongering;” physicians
as prescribers, gatekeepers, and “developers of new medicines often in alliance with the
industry;” affluent publics in consumer-oriented societies who use information
technology and become “expert patients;” and governments and insurance companies (for
a discussion of these forces see the chapter by Abraham and Davis in this volume).
Pharmaceuticalization scholarship builds on and has explicit ties with
medicalization scholarship, but scholars generally agree that pharmaceuticalization can
occur without medicalization, and vice versa. Studies of the pharmaceutical process, like
those of the medicalization process, typically do so from the perspective of modern social
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theory. They draw inspiration and logic from the natural sciences, adopt an engineering
mentality (Lock 2004), trace the drug development and approval process in terms of
“countervailing powers” (Busfield 2006), and identify pharmaceuticalization as a search
for control of behavioral, bodily, or social conditions (Bell and Figert 2012a).
In our work, we show that current research in anthropology provides a useful
layer of understanding pharmaceuticalization (Bell and Figert 2012a). Whereas
sociologists primarily study pharmaceuticalization by focusing upon power, economics
and treatments in the West and the dynamics of the largest pharmaceutical companies
(often called Big Pharma) and high-income nation states, anthropologists focus primarily
upon the issues of pharmaceuticals in low or middle-income countries where the political
economic systems are often post-colonial or post-communist. This focus has allowed
anthropologists to conceptualize pharmaceuticalization differently and to examine
political, economic and organizational dynamics that are less visible in the studies by
sociologists.
The pharmaceuticalization of public health as outlined by Biehl and others
suggests that there is both a political and an economic rationality to cutting back on
disease prevention efforts in favor of a national pharmaceutical distribution policy (Biehl
2007, Whitmarsh, 2008). From a neoliberal state perspective, it is cheaper and more
efficient to diagnose and treat diseases pharmaceutically than to prevent them through
traditional public health measures. The process of pharmaceuticalization and the policy of
the pharmaceuticalization of public health are key factors in the expansion of the use of
pharmaceuticals to treat medical and social problems. These two “strands” of
pharmaceuticalization theory and research shed light on the uneven and unequal global
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processes of pharmaceuticalization. Thus, in the global North, pharmaceuticalization is
primarily about expanding social and behavioral diagnostic categories and diagnoses,
while in the global South, pharmaceuticalization is primarily about expanding access to
medicines and public health or of increasing testing sites for pharmaceutical clinical
trials. In the global South, citizens and nongovernmental organizations (NGOs) – often
in response to the HIV/AIDS epidemic – have mobilized and demanded access to certain
drugs or treatments.
The pharmaceuticalization of public health scholarship also brings a postmodern
framework to understanding pharmaceuticals today. We use the term “postmodernity” to
refer to society based on information technology and characterized by interaction,
contingency, fragmentation, volatility, and hybridity. In postmodern society, boundaries
are blurred, such as between public/private, government/corporation, expert/lay,
human/animal, and human/machine. Postmodern theory assumes that the political
economic, cultural, organizational, and technoscientific trends and processes of
pharmaceuticalization are complex and mutually constituted. The pharmaceuticalization
of public health is manifest in macrostructural changes as well as in new personal
identities, subjectivities, and configurations by seeking to connect global dynamics
among states, non-governmental organizations (NGOs), pharmaceutical companies, and
local communities (see Petryna et al. 2006; Clarke et al. 2010; Bell and Figert 2012a).
Much work remains to be done in exploring how pharmaceuticalization works
globally, and we must recalibrate the balance between studies of the global North and
global South (e.g., Brazil [Biehl 2006, 2007], Barbados [Whitmarsh 2008], India [Sunder
Rajan 2007, 2012], Thailand, Uganda and South Africa [Petty and Heimer 2011], and
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Poland [Petryna 2009]). The pharmaceuticalization of public health can be used to make
sense of dynamics where states with less power and wealth define free access to
pharmaceuticals as rights of citizenship (and a new subjectivity, pharmaceutical
citizenship). It can make visible ways that pharmaceuticalization can contribute to the
creation of new democratic tools for individuals, activist groups, and states. For example,
participation in clinical trials of pharmaceuticals can be a strategy to gain access to drug
treatments and medical care and accomplish what people believe to be in their best
economic and medical interests. For societies with few resources, pharmaceuticalization
can be a strategy for realizing the rights of citizens and improving population health. Yet
defining rights of citizenship as access to pharmaceuticals creates new possibilities for
entering into the grip of biomedical power, forecloses other approaches to improving
population health and wellbeing, and contributes to the pharmaceuticalization of public
health.
Standardization and Global Clinical Trials
In this section, we show how the global expansion of clinical trials and the global
standardization of research procedures and ethics foster pharmaceuticalization and the
pharmaceuticalization of public health. Standardization is the process of constructing
uniformities across space and time. These uniformities, created by multiple historically
situated actors, are expressed in standards (Timmermans and Berg 2003). The standards,
in turn, coordinate people and things in “new configurations” (Timmermans and Epstein
2010: 83). The standardization of both research procedures and ethics has facilitated the
proliferation of global clinical trials, the portability of results and the global expansion of
markets. These standards are expressed in and enforced by international organizations
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(e.g., the International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use [ICH], the Agreement on Trade Related
Aspects of Intellectual Property [TRIPS]), regulatory agents of the state (e.g., US Food
and Drug Administration, Drug Controller-General of India), professional governance
(e.g., the Declaration of Helsinki), and codes and formal laws (e.g., The Nuremberg
Code, The Belmont Report). At the same time the development of global clinical trials
has coordinated people and things into new configurations (e.g., “Contract Research
Organizations”), and subjectivities (e.g., “treatment naïve populations,” “treatment
saturated populations” discussed later in this chapter). Increasingly, clinical
pharmaceutical trials have been privatized by the development of a contract research
industry (Fisher 2006, 2009).
While not all clinical trials are conducted with pharmaceuticals, many studies by
anthropologists and sociologists focus on the expansion of global clinical pharmaceutical
trials as primary components of pharmaceuticalization (e.g., Petryna, Lakoff and
Kleinman 2006, Dumit 2012a, Williams, Gabe and Davis 2008). In 2006, more than 2.4
million Americans participated in clinical trials (Dumit 2012a:18). Since the 1990s, the
number of international subjects involved in clinical trials – including pharmaceutical
trials – has grown substantially, from 4000 in 1995 to 400,000 in 1999 (Petryna
2006:189). Until recently, much of the pharmaceutical and clinical research was
conducted in the US and Western Europe, but today it is likely to be conducted
elsewhere. During February 2013, 29,623 clinical trials were actively recruiting study
participants, and almost half of the trials (49%) were seeking subjects exclusively outside
the United States (http://www.clinicaltrials.gov/ Feb. 11, 2013).
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There are multiple, multidirectional reasons that clinical trials are pushed and
pulled globally. The time between first identification of an active agent with therapeutic
potential and formal approval for marketing is 10-15 years and each new drug costs $897
million to develop (Busfield 2006; Petryna et al. 2006: 11). 1 Developing countries in
particular are likely to have fewer regulations and a looser regulatory apparatus for
enforcing ethical and research standards. They provide cheaper labor and lower
infrastructure costs, reducing overall expenses of clinical trials by 30 to 50 percent
(Sunder Rajan 2007: 72). In addition they reduce the time line for clinical testing by
accelerating subject recruitment and improving the likelihood of showing drug
effectiveness because their populations are more likely to be pharmaceutically or
treatment naïve, that is to have little or no previous access to pharmaceuticals and no
background medications at the time of the trial that might confound results.
Clinical trials are pushed and pulled globally to reduce time and expense both
because in the US and Western Europe patients and potential human subjects are
increasingly skeptical of drug trials and because patients and physicians in Eastern
Europe, Eurasia and the global South need the resources that pharmaceutical companies
offer. The global expansion of clinical trials opens the possibility for individuals and
communities to gain access to medicines otherwise unavailable to them (Biehl 2006,
Nguyen 2005). The use of these pharmaceutically naïve subjects “creates efficient results,
free of statistical noise” (Petryna 2007: 37).

Standardizing global research procedures
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The standardization of clinical trials and research procedures and the actors
involved in this standardization in the 1990s played an important role in the expansion of
global clinical trials and pharmaceuticals. Global technical standards specifically for
pharmaceutical research began to be institutionalized in the 1990s, exemplified by the
development of Contract Research Organizations (CROs) and the International
Conference on Harmonization (ICH). CROs create mobile clinical trial environments and
trial results. CROs are private, for profit companies that implement and manage global
clinical trials for large multinational pharmaceutical companies. Fisher (2009) reports
that over 75 percent of clinical drug trials in the US are now conducted in the private
sector. Since the US is the largest pharmaceutical market in the world and by some recent
estimates Big Pharma makes two-thirds of its profits in the United States, the process for
pharmaceutical testing in the US and its legitimation by the US Federal Food and Drug
Administration (FDA) guide how pharmaceutical companies conduct clinical trials
outside as well as inside the US (Harris 2013). There are four distinct phases of
pharmaceutical testing for approval by the FDA. Each phase is designed to build upon the
others and requires increasing numbers of participants. If a drug is determined to be safe
in a small group of healthy volunteers (Phase 1with 20-80 participants) and effective in
treating the targeted condition (Phase 2 with 100-300 participants), the drug will move to
Phase 3 which is characterized by a large group of participants (usually between 1,000
and 3,000 people) to confirm the effectiveness and scrutinize any possible side effects. In
some cases, a Phase 4 (also called "post-marketing") trial will be conducted. This phase is
primarily observational and is non-experimental and may explore new uses or dosages, or
use in new populations.
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CROs work in and serve as the “middlemen” or service providers (see Fisher,
2009). In primarily low- and middle- income countries, CROs identify research sites,
clinics, practitioners and recruit human subjects. International CRO’s are important in the
process of moving a drug from Phase 2 to Phase 3, because of the need for large numbers
of participants. Their main source of revenue comes from conducting clinical trials
efficiently and cost effectively (Petryna 2006: 38). CROs also help to ensure that clinical
research complies with accepted technical standards and national and international ethical
guidelines and thereby makes “data from various international sites portable to and usable
within the US drug approval process” (Petryna 2011:307).
From 1992 to 2004 the CRO market grew from $1 billion to $7 billion and by
2004 there were more than 1000 CROs worldwide. A recent survey of CROs found that
pharmaceutical companies outsourced a wide variety of functions to CRS from design to
site selection, study conduct, and medical writing (Getz and Vogel 2009). Sunder Rajan
(2007) highlights the role that consulting firms, such as A.T. Kearney, play in helping
Big Pharma find international testing sites. Kearney developed an attractiveness index for
clinical trials (calculated by evaluating patient availability, cost efficiency, relevant
expertise, regulatory conditions and national infrastructure) and determined that the most
favorable pharmaceutical testing sites were China, India and Russia (Bailey et al. 2009:
57). Sunder Rajan (2012: 332) points out that unlike the pharmaceutical companies for
which the locus of value lies in the valorized expansion of health, the locus of value for
CROs is the valorized expansion of pharmaceutical clinical trials.
The development of the CRO industry occurred concurrently with and was
fostered by the introduction of guidelines for clinical trials established in 1990 by the
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International Conference on Harmonization (ICH). The ICH was the product of
international pharmaceutical regulators from the US, the European Union, Japan and the
pharmaceutical industry (see http://www.ich.org/about/vision.html). In effect, the ICH
established uniform research and technical requirements and standards such as
randomized controlled trials (RCT) – in which subjects are randomly assigned to either a
treatment group or a control group – in drug testing. At first the use of these standards
“made clinical data from international research sites transferable and acceptable to
regulatory bodies in” the major markets of Europe, Japan, and the United States (Petryna
2007: 30). Since 2007 the ICH has opened up its process and expanded its reach beyond
these major markets. For example, representatives of drug regulatory agencies from
Australia, Brazil, China, Chinese Taipei, Russia, India, Singapore, and South Korea have
been invited to attend the ICH (http://www.ich.org/). Together CROs and the ICH
construct uniform standards for global clinical trials across time and space.

Standardizing global research ethics and ethical variability
The successful expansion of global pharmaceutical research depends on adhering
to certain established international ethical standards. At the same time, global expansion
fosters the transformation of these same ethical standards. Since the 1980s, the global
dynamics of the pharmaceutical industry have played “an important role in shaping
contexts in which ethical norms and delineations of human subjects are changing”
(Petryna 2006: 34). In the common narrative of research ethics, ethical standards for
clinical trials can be traced to the Nuremberg Code (1947) and the Declaration of
Helsinki (1964), which provide both a moral framework and an explanation for how and
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why human subjects need and are protected in ordinary scientific and medical practice
(Hoeyer 2009). In this section we argue that recent revisions to the Declaration of
Helsinki have created a new configuration of unethical trials, that global ethical standards
often produce the impetus, justification and tools for turning healthy populations into
experimental subjects, and that a modernist frame of understanding cannot account for
these effects.
There was no international statement differentiating between legal and illegal
human experimentation until the Nuremberg Code (a set of ten points related to human
experimentation targeting Nazi doctors and scientists) was established in 1947 during the
World War II war crimes tribunal. The voluntary consent of the prospective human
subject is the bedrock of the Nuremberg Code. The Code requires that all unnecessary
physical and mental suffering should be avoided, the degree of risk should never exceed
the benefit which may derive from the tested drug or treatment and the research should be
conducted by scientifically qualified persons. 2 The Nuremberg Code continues to serve
as a “blueprint for today’s principles that ensure the rights of subjects in medical
research” (Shuster 1997: 1436) although some scholars have convincingly argued that it
was frequently ignored by scientists and physicians because it was really only for Nazi
“barbarians” and not everyday scientists and physicians (Katz, 1992, Rothman, 1991 and
Hoeyer, 2013).
The Declaration of Helsinki, 3 established in 1964 by the World Medical
Association, seeks to guide physicians in research with human subjects, and leaves intact
physicians’ civil, criminal and ethical responsibilities under the laws of their own
countries. Katz (1992) argues that in contrast to the Nuremberg Code, in the Declaration
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of Helsinki concerns over the advancement of science began to overshadow concerns over
the integrity of person. The Declaration has been amended regularly since 1964 but the
most controversial amendments have to do with the issues of the use of placebos,
international testing, informed consent, and access to treatment at a trial’s conclusion.
Effectively, by establishing that placebo trials are acceptable only when no proven
treatment already exists, the 1996 and 2000 revisions to the Declaration created a new
configuration of unethical clinical trials in the US and other countries. In the 1996 revision
to the Declaration, the idea of a placebo, an inert substance or one containing no
medication, is introduced for the first time:
In any medical study, every patient – including those of a control group, if any –
should be assured of the best proven diagnostic and therapeutic method. This does
not exclude the use of inert placebo in studies where no proven diagnostic or
therapeutic method exists (as quoted in Carlson et al 2004: 698).
In contrast, the 2000 revision to this paragraph reads:
The benefits, risks, burdens and effectiveness of a new method should be tested
against those of the best current prophylactic, diagnostic, and therapeutic
methods. This does not exclude the use of placebo, or no treatment, in studies
where no proven prophylactic, diagnostic or therapeutic method exists (as quoted
in Carlson et al. 2004: 700, emphasis in original).
The US and the FDA have not recognized these recent amendments to the Declaration
regarding the preference for testing new pharmaceuticals and vaccines against the best
current methods instead of against a placebo, arguing that this would inhibit the
development of good science and efficacious drugs (see Wolinsky 2006). Pharmaceutical
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trials funded by the US government and its agencies continue to use placebo testing
throughout the world.
International ethical guidelines for research involving human subjects – such as
the 1996 and 2000 revisions to the Declaration of Helsinki – are being recast along with
the movement of clinical trials globally. Revisions concerning the use of placebos in
pharmaceutical research can be traced a growing concern about international studies of
maternal-fetal HIV transmission in developing countries (Carlson et al., 2004). In an
article published in the New England Journal of Medicine, Lurie and Wolfe (1997)
questioned why studies outside the US sponsored by a US government agency, the
National Institutes of Health, used a placebo design even though there was already a
known and effective treatment to prevent maternal-fetal HIV transmission available in
the US. Supporters of the study design and implementation argued that “local cultural
variables and deteriorated health services” made placebos acceptable and that it would be
a “paternalistic imposition” for the US to determine the appropriate design of research in
regions of such poverty (Petryna 2007: 28-29). Similarly, local and national authorities in
these regions argued that they should determine research conduct and treatment
distribution.
As clinical pharmaceutical trials have become globalized, STS scholars and others
have examined how enacting ethical standards internationally takes place. Petryna (2007)
argues that “ethical variability” - the creation of local standards to recruit human subjects
for clinical and pharmaceutical research – produces the conditions for the exploitation of
“Third World subjects.” Ethical variability legitimates the modification of ethical
standards according to the local contexts of clinical trials. It has evolved as a tactic for
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weighing immediate health benefits or outcomes against protection and safety
considerations and not as a strategy for being sensitive to those persons asked to enroll in
clinical pharmaceutical trials (Petryna 2007; Farmer and Campos 2004).
More generally, participants and clinics always adjust and use workarounds in
implementing ethical standards. Drawing from their study of HIV treatment and clinical
trials in the global North (2 US clinics) and South (one each in Thailand, Uganda and
South Africa), Heimer and colleagues show that in all clinics, both North and South,
“neither research subjects nor the recruitment and consent process actually live up to the
ethical ideals as embodied in the institutions of informed consent” (Heimer, 2012: 24).
When researchers or state agencies try to implement any local or global standards, it is
inevitable that the practices will include workarounds and adjustments.
Social scientists have observed repeatedly that the Nuremberg Code, Declaration
of Helsinki, and similar ethical standards for research assume autonomy and choice of the
individual “and downplay social and economic constraints on individual agency”
(Marshall and Koenig 2004: 255; see also Fisher, 2009). The result is that global ethical
standards often provide the impetus, justification and tools for turning healthy
populations into experimental subjects. As Angell warned in 1997:
Research in the Third World looks relatively attractive as it becomes better
funded and regulations at home become more restrictive. Despite the existence of
codes requiring that human subjects receive at least the same protection abroad as
at home, they are still honored partly in the breach. The fact remains that many
studies are done in the Third World that simply could not be done in the countries
sponsoring the work. Clinical trials have become a big business, with many of the
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same imperatives. …Those of us in the research community need to redouble our
commitment to the highest ethical standards, no matter where the research is
conducted, and sponsoring agencies need to enforce those standards, not undercut
them (1997: 849).
To summarize, on the one hand the construction of a universal standard or ethical
code of conduct for pharmaceutical clinical trials appears to be “good” or “just” because
it is sensitive to imbalances of power and money. This interpretation would work within a
modernist framework. On the other hand, treating all people as equal in a world
characterized by inequality effectively serves to reinforce that inequality. The
harmonization of ethical codes or standards for global clinical trials obfuscates the
reproduction and exacerbation of global inequality. Furthermore all global standards are
practiced and implemented locally and thus entail local workarounds and adjustments in
the field. The modernist frame, dominant in sociological accounts of
pharmaceuticalization, cannot account for all of these practices and effects. A
postmodern framework for understanding global clinical pharmaceutical trials helps the
analyst move away from an either/or framing to understand that ethical variability is not
always bad and standardization is not always good. Both variability and, as we discuss
next, standardization, can produce different outcomes depending upon local settings and
histories.
Disruptions to Standardization?
In this section we show how standard sociological and modernist conceptual
frameworks for understanding pharmaceuticalization are simply insufficient to explain
the expansion of clinical trials to the Global South or how in some respects those in low
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resourced countries benefit more by participation in these trials than those in high
resourced countries. We address the question of how an understanding of standards and
rules sheds light on the conceptualization and processes of global pharmaceuticalization
and the pharmaceuticalization of public health, and we use work on the expansion of
pharmaceutical clinical trials in India by Sunder Rajan to illustrate our argument (Sunder
Rajan 2005, 2007, 2012).
As discussed above, with the expansion of the number of clinical trials, the need
for human subjects increases, and trials are more and more likely to be conducted in the
global South with the goal of producing portable results. One reason given for this is that
these countries are seen as having fewer regulations and a looser regulatory apparatus
(Petryna, 2009). Since the 1990s, India has become incorporated into the globalized drug
development sector. In his study of global pharmaceutical economies, Sunder Rajan
(2007, 2012) contests the assumptions that ethical standards are “stricter” in the West. In
2005 India converted its guidelines for informed consent into laws (Schedule Y) and is
now the only country in the world “where the violation of good clinical practice is a
criminal rather than a civil offence” (Sunder Rajan 2007: 74). Indeed, Schedule Y
focuses on ways of insuring informed consent from subjects who are poor and illiterate.
In many ways, this means that local ethical standards in India are especially tight, and
global harmonization could diminish the possibility of developing local standards such as
these. On the surface, the informed consent process in India provides potential
experimental subjects with the choice to freely participate or not participate in clinical
pharmaceutical trials. And yet, although subjects may freely give consent to participate in
clinical trials, their access to pharmaceuticals ends along with the end of the trials.
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Experimental subjects are still exploited, or in Sunder Rajan’s terms “merely risked”
because for this population, clinical experimentation is not linked to the benefit of
subsequent therapeutic access.
The harmonization of ethical standards provides the conditions for continued
global pharmaceutical and economic inequality. In India, the apparatus of clinical trials
simultaneously accepts Western bioethics standards of informed consent and rigorously
applies them so its research results can travel. At the same time, its population will bear
the burden without the benefit of research results. In its careful attempt to adhere to
global (universal) standards, India creates conditions for the exploitation of Indian bodies
(and by implication of Third World subjects more generally) because of the real
economic rewards and the potential for further inclusion in the global pharmaceutical
economy.
In the US and most of the world, there is less attention to the ethics of how
poverty and specific forms of indebtedness shape consent and decisions in
pharmaceutically naïve populations 4 or whether the burden of research is balanced with
tangible therapeutic benefits after completion of trials (Fisher, 2009). Advocacy groups
have learned to fight for access to pharmaceuticals for citizens in the global south (as
they did successfully in Brazil) (see Biehl 2004, 2007) and for the importation of more
affordable generic versions of medicines from foreign manufacturers, as Brazil,
Argentina and South Africa have done for AIDS medicines (WHO Drug Information v.
19, no. 3 2005, Access to Medicines). 5 One way that pharmaceutical companies respond
to such activism and pressure is by providing therapeutic access through their
compassionate use programs “which make the drugs tested in Phase 3 trials available to
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the sick volunteers for a fixed period of time after completion of the trial” (Sunder Rajan
2007: 79).
The dynamics of clinical pharmaceutical trials in India, Barbados and Brazil are
representative of new forms of an international bioeconomy in which nations, the
pharmaceutical industry and other corporate actors work to create global experimental
sites. In this new phase of capitalism, clinical pharmaceutical trials establish places where
experimental subject populations exchange human bodies for payment in the form of cash
or access to treatment (Sunder Rajan 2006, Dumit, 2012a). In this context, the problem
of the exploitation of third world “merely risked” subject populations is not the result of
the harmonization of standards—either looser standards pulling clinical trials to the
global South or tighter standards protecting experimental subjects in the global South—
but reflects the reorganization and reconceptualization of global capital in relation to “life
itself” since the 1980s.
New Configurations
Although the global expansion of clinical trials works unevenly throughout the
world, there is some evidence that in some respects physical sites of the new bioeconomy
such as health or pharmaceutical clinics in "poor" countries benefit more from these trials
than do clinics in "rich" countries. Thus, in a study of clinical trials in countries at
varying levels of development – the US, South Africa, Thailand and Uganda – Petty and
Heimer (2011) and Heimer (2012) show that global HIV research can be more beneficial
to countries in the Global South than to the US. Clinics reconfigure their local practices
of care and treatment to bring them in line with ICH standards: to produce accurate,
complete, and verifiable study data and to ensure “that the rights and well-being of
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human subjects are protected” (Petty and Heimer 2011: 350). These reconfigurations
include upgrading laboratory facilities to be able to do the complicated tests required by
clinical trials and using laboratory equipment in study-specific ways to produce
standardized results. The new configurations vary depending on clinics’ existing
resources, routines, and relationships. In poorer countries, where equipment is often in
short supply funders often pay to improve laboratory facilities so clinics can participate in
research (Petty and Heimer 2011: 342). Once laboratory facilities are upgraded, clinics in
poorer countries can employ them in both research and treatment. However, because
materials are less easily repaired, replenished, or replaced, “the overall effect of altering
the material environment in poorer countries is likely to be modest unless the flow of
funds is very stable” (Petty and Heimer 2001: 357). By contrast, in richer countries,
research-provided technologies duplicate already available medical equipment and doing
the research has a less beneficial effect.
Clinical pharmaceutical trial participation can also reshape the clinics in ways that
smooth the way for their later adoption of clinical research findings. The everyday
actions and results of introducing new jobs, technologies, and standard operating
procedures for clinical trials is as important to changing medical practice as is the
influence of subsequent research results. Petty and Heimer (2011) identified three types
of practices that are changed in the doing of clinical research. The introduction of new
research-mandated tools alters the material environment, the introduction of new and/or
retrained staff reorganizes staff relationships in the clinics, and the adoption of research
practices changes clinic priorities. In other words, conducting clinical research is not just
a means of testing new treatments that subsequently change medical practice. The new
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routines for clinical trials change clinic practices so that new therapies will fit local
conditions and can be translated into medical care (Petty and Heimer 2011).
In the process of conducting clinical trials, standardization of actions and practices for
doing the research reshapes the clinics and gives further agency and sometimes
bargaining power to the clinic staff to advocate for their patients.
In reconfiguring their local practices in order to participate in global clinical trials,
Petty and Heimer (2011) found that clinics in the US and the global South fostered a
pharmaceutical approach to public health that ultimately necessitated and created reliance
upon technoscience and biomedicine beyond money and supplies. More generally,
participation in pharmaceutical clinical trials creates regimes of practice and enforces
ways of thinking and action that focus on pharmaceutical solutions. It forecloses other
ways of thinking about and treating public health problems. While providing certain
kinds of benefits to resource poor countries, the pharmaceuticalization of public health
projects (vaccines, pharmaceutical testing or treatments) excludes cheaper and more
effective ways to treat the health of the general population. When clinics change how
they work and think about the way to treat patients in adjusting to pharmaceutical trials,
they narrow the gaze and focus to one that concludes pharmaceuticals are the ultimate
solution to improving public health. This is especially problematic in states with fewer
resources because it ultimately narrows the options to more technological and capital
intensive solutions.
Conclusion
In this chapter we have argued that global research and ethical standards of
pharmaceutical development – especially in global clinical trials—are institutionalized,
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disrupted and/or shaped by nation states and international bodies, local and global
cultures, and multinational pharmaceutical firms. The standard pharmaceuticalization
and modernist framework uses one of two possible narratives about why and how clinical
trials and ethical practices have become standardized. In the first narrative, the institution
of medicine in conjunction with international regulatory bodies successfully developed
and adopted scientific and ethical frameworks for the conduct of clinical trials globally.
The result is better, well-designed, portable, and ethical scientific research and
pharmaceutical products. The second explanation suggests an alternative result, that
global bodies are being exploited by the capitalistic expansion of pharmaceutical
companies into the global South in the pursuit of cheaper trials and an undermedicalized
surplus army of available bodies.
But neither of these modernist frames fully captures what is going on with global
pharmaceutical trials. Ultimately, the outcomes of the clinical trial process internationally
do not fit standard modernist narratives of either exploitation or the ethical advance of
scientific research. A modern perspective on global clinical trials employs an either/or
analysis. Global clinical trials can also be seen through a postmodern framework that
captures the uneven and contradictory character of pharmaceutical trials occurring
throughout the world. We show that bodies used in clinical trials may or may not ever
benefit from pharmaceutical development and may or may not be exploited during and
after the trials conclude. A postmodern perspective enables a more subtle analysis:
pharmaceutical and clinical trial innovations are made possible by and at the same time
foster major shifts in the global political economy. This ambiguity is especially apparent
in the pharmaceuticalization process. Global pharmaceutical trials and ethical research
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standardization are complex, global, and multi-sited and involve remaking the technical,
organizational, and institutional infrastructures of the life sciences and biomedicine. The
pharmaceutical transformation of life and approach to public health is associated with a
new, postmodern, era in medicine and society more broadly.
To support our argument, we analyzed two cases: Sunder Rajan’s study of clinical
trials in India and Petty and Heimer’s study of global clinical research in HIV clinics.
Both of these cases explain how local circumstances help to make sense of
pharmaceuticalization and the pharmaceuticalization of public health and both cases are
better explained by a more postmodern than a modern frame. Sunder Rajan shows that
the particular history of the pharmaceutical industry in India, Indian CROs, and labor
exploitation, are explanatory "forces" that have led to India's desire to be a location for
clinical trials. In spite of the fact that most Indians may not benefit directly from
pharmaceutical research, some poor and illiterate Indians do gain access to clinical trials
after informed consent is carefully administered to them. Using Sunder Rajan’s case of
India, we conclude that a modernist explanation of either economic exploitation or
benefit does not go far enough.
In the second case we show that the global expansion of clinical trials works
unevenly throughout the world and further that in some respects clinics in "poorer"
countries benefit more from these trials than do clinics in "richer" countries. For example,
Petty and Heimer document how an unintended consequence of participating in global
clinical HIV trials for those in poor countries is the reconfiguration of their organizational
and medical practices. An additional consequence is the pharmaceuticalization of public
health even though it may be a more expensive strategy. Through their participation in
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clinical trials, clinics create a regulatory, clinical and institutional apparatus that fosters a
pharmaceutical approach to HIV. As they write: “… the costs of new pharmaceuticals
can easily overwhelm the healthcare systems of poor countries, when investing in the
lower-end of healthcare would surely be wiser” (Petty and Heimer 2011: 357). Public
health becomes pharmaceuticalized with significantly different procedures and
consequences. The contradictions, reversals, and production of new subjectivities such as
pharmaceutical citizenship or reconfigured clinics are better explained by a postmodern
than a modern theory of pharmaceuticals.
Finally, both of these cases show that while in theory the call for global ethical
research standards appears to be a modern and scientific way forward, in reality the
implementation of these standards is not “standard” and not always beneficial to clinics
and patients in poor countries. Clinics or countries encourage and produce
“workarounds” in their efforts to conform to standards. Distinctions such as ethical
variability versus standardization—and the modernist assumptions and interpretations of
their effects--fail to capture some of the surprising ways in which standards and
variability shape the experiences of people in very different parts of the world who are
part of a global pharmaceutical system, and thus modernist approaches do not help us
fully comprehend the dynamics of global health inequality.

26

References Cited

Abraham, J. 2007. "Building on Sociological Understandings of the Pharmaceutical Industry or
Reinventing the Wheel? Response to Joan Busfield's 'Pills, Power, People'." Sociology
41: 727-736.
—. 2010a. "The Sociological Concomitants of the Pharmaceutical Industry and Medications." In
Handbook of Medical Sociology, edited by C. Bird, P. Conrad, A. M. Fremont, and S.
Timmermans, 290-308. Nashville: Vanderbilt University Press.
—. 2010b. Pharmaceuticalization of society in context: theoretical, empirical and health
dimensions. Sociology, 44(4), 603e622.
Angell, Marcia. 1997. "The ethics of clinical research in the Third World." New England Journal
of Medicine-Unbound Volume 337.12 (1997): 847-849.
Bailey, W., C. Cruickshank, and N. Sharma. 2009. "Make Your Move: Taking Clinical Trials to
the Best Location." In Executive Agenda, A. T. Kearney: A. T. Kearney.
http://www.atkearney.com/ retrieved January 13, 2013, 56-62.
Bell, S. E. and A. E. Figert. 2010. "Gender and the Medicalization of Health Care " In Palgrave
Handbook of Gender and Healthcare, edited by E. Kuhlmann and E. Annandale,107-122
City: Palgrave Macmillan.
Bell, S. E. and A. E. Figert. 2012a. "Medicalization and Pharmaceuticalization at the
Intersections: Looking Backward, Sideways and Forward." Social Science & Medicine
75: 775-783.
Bell, S. E. and A. E. Figert. 2012b. "Starting to Turn Sideways to Move Forward in
Medicalization and Pharmaceuticalization Studies: A Response to Williams et. al." Social

27

Science & Medicine 75: 2131-2133.
Biehl, J. 2004. "The Activist State: Global Pharmaceuticals, AIDS, and Citizenship in Brazil."
Social Text 22: 105-132.
Biehl, J. 2006. "Pharmaceutical Governance." In Global Pharmaceuticals: Ethics, Markets,
Practices, edited by A. Petryna, A. Lakoff, and A. Kleinman, 206-239. Durham: Duke
University Press.
Biehl, J. 2007. "Pharmaceuticalization: AIDS treatment and global health politics."
Anthropological Quarterly 80: 1083-1126.
Boston Women's Health Book Collective. 1973. Our Bodies, Ourselves: A Book by and for
Women. New York: Simon & Schuster.
Brown, P. and S. Zavestoski. 2005. Social Movements in Health. Oxford, UK: Blackwell
Publishing.
Busfield, J. 2006. "Pills, Power, People: Sociological Understandings of the Pharmaceutical
Industry." Sociology 40: 297-314.
—. 2010. "'A Pill for Every Ill': Explaining the Expansion in Medicine Use." Social Science &
Medicine 70: 934-941.
Carlson, R. V., K. M. Boyd, and D. J. Webb. 2004. "The Revision of the Declaration of Helsinki:
Past, Present, and Future." British Journal of Clinical Pharmacology 57: 695-713.
Clarke, A., J. Shim, L. Mamo, J. R. Fosket, and J. R. Fishman. 2010. Biomedicalization:
Technoscience Health and Illness in the U.S. Duke University Press.
Clarke, A. E., L. Mamo, J. R. Fishman, J. K. Shim, and J. R. Fosket. 2003. "Biomedicalization:
Technoscientific Transformations of Health, Illness, and U.S. Biomedicine." American
Sociological Review 68: 161-194.

28

Conrad, P. 2005. "The Shifting Engines of Medicalization." Journal of Health and Social
Behavior 46: 3-14.
Crossley, N. 2006. Contesting Psychiatry: Social Movements in Mental Health. London, UK:
Routledge.
Dumit, J. 2012a. Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham,
NC: Duke University Press.
—. 2012b. "Prescription Maximization and the Accumulation of Surplus Health in the
Pharmaceutical Industry: The_BioMarx_Experiment." In Lively Capital:
Biotechnologies, Ethics, and Governance in Global Markets, edited by K. Sunder Rajan,
45-92. Durham and London: Duke University Press.
Farmer, P. 2003. Pathologies of Power: Health, Human Rights, and the New War on the Poor.
Berkeley, CA: University of California Press.
Farmer, P. and N. G. Campos. 2004. "New Malaise: Bioethics and Human Rights in the Global
Era." Journal of Law, Medicine & Ethics 32: 243-251.
Figert, A. E. 2011. "The Consumer Turn in Medicalization: Future Directions with Historical
Foundations." In The Handbook of the Sociology of Health, Illness & Healing: Blueprint
for the 21st Century, edited by B. Pescosolido, J. Martin, J. Mcleod, and A. Rogers, 291307. New York: Springer.
Fisher, J. A. 2006. “Co-ordinating ‘ethical’ clinical trials: the role of research coordinators in the
contract research industry.” Sociology of Health & Illness, 28: 678–694.
Fisher, J.A. 2009. Medical Research for Hire: The Political Economy of Pharmaceutical Clinical
Trials. New Brunswick, NJ: Rutgers University Press.

29

Gabe, J. and Bury, M. 1988. “Tranquillisers as a Social Problem.” Sociological Review 36: 320352.
Getz, K. A. and J. R. Vogel. 2009. "Successful Outsourcing: Tracking Global CRO Usage."
Applied Clinical Trials 18: 42-50.
Glickman, S. W., J. G. McHutchison, E. D. Peterson, C. B. Cairns, R. A. Harrington, R. M.
Califf, and K. A. Schulman. 2009. "Ethical and Scientific Implications of the
Globalization of Clinical Research." New England Journal of Medicine 360: 816-823.
Gutmann, A. and J. W. Wagner et al. 2011. "Moral Science: Protecting Participants in Human
Subjects Research." edited by Presidential Commission for the Study of Bioethical Issues.
Washington, DC: U.S. Department of Health and Human Services.
Harris, G. 2013. “Patent’s Defeat in India is Key Victory for Generic Drugs” NYTimes, April 1.
Hartmann, B. 1987. Reproductive Rights and Wrongs: The Global Politics of Population Control
and Contraceptive Choice. New York: Harper and Row.
Heimer, C. A. 2012. "Inert Facts and the Illusion of Knowledge: Strategic Uses of Ignorance in
HIV Clinics." Economy and Society 41: 17-41.
Hoeyer, K. “Informed Consent: The Making of a Ubiquitous Rule in Medical Practice.”
Organization 16:267-288.
Katz, J.1992. ‘The Consent Principles of the Nuremberg Code: Its Significance for Then and
Now’, in G. J. Annas and M. A. Grodin (eds) The Nazi Doctors and the Nuremberg
Code, pp. 227–39. Oxford: Oxford University Press.
Lock, M.M. 2004. “Medicalization and the Naturalization of Social Control.” In Encyclopedia of
Medical Anthropology; Health and Illness in the World’s Cultures, edited by C. W.
Ember and M. Ember, 116-124. New York: Kluwer Academic/Plenum.

30

Marshall, P. and B. Koenig. 2004. "Accounting for Culture in a Globalized Bioethics." Journal
of Law, Medicine & Ethics 32: 252-266.
Nguyen, V. K. 2005. "Antiretroviral Globalism, Biopolitics, and Therapeutic Citizenship." In
Global Assemblages, edited by A. O. and S. J. Collier, 124-144. Malden, MA: Blackwell
Publishing.
Nichter, M. 1996 [1989]. "Pharmaceuticals, the Commodification of Health, and the Health
Care-Medicine Use Transition." In Anthropology and International Health: Asian Case
Studies, Theory and Practice in Medical Anthropology and International Health, edited
by M. Nichter and M. Nichter, 265-326. Amsterdam: Gordon and Breach Publishers.
Petryna, A. 2006. "Gloalizing Human Subjects Research." In Global Pharmaceuticals: Ethics,
Markets, Practices, edited by A. Petryna, A. Lakoff, and A. Kleinman, 33-60. Durham,
NC: Duke University Press.
—. 2007. "Clinical Trials Offshored: On Private Sector Science and Public Health." BioSocieties
2: 21-40.
—. 2009. When Experiments Travel: Clinical Trials and the Global Search for Human Subjects.
Princeton, NJ: Princeton University Press.
—. 2011. "Pharmaceuticals and the Right to Health: Reclaiming Patients and the Evidence Base
of New Drugs." Anthropological Quarterly 84: 305-330.
Petryna, A., A. Lakoff, and A. Kleinman. 2006. Global Pharmaceuticals: Ethics, Markets,
Practices. Berkeley: University of California.
Petty, J. and C. A. Heimer. 2011. "Extending the Rails: How Research Reshapes Clinics." Social
Studies of Science 41: 337-360.
Reverby, S. M. Ed. 2000. Tuskegee's Truths: Rethinking the Tuskegee Syphilis Study. Chapel

31

Hill: University of North Carolina Press.
—. 2011. "Editorial: Tuskegee: Could it Happen Again?" Postgraduate Medical Journal 77:
553-555.
Rose, N. and C. Novas. 2005. "Biological Citizenship." In Global Assemblages: Technology,
Politics, and Ethics as Anthropological Problems, edited by A. Ong and S. J. Collier,
439-463. City needed: Blackwell.
Shostak, S. 2010. "Marking Populations and Persons at Risk: Molecular Epidemiology and
Environmental Health." In Biomedicalization: Technoscience, Health, and Illness in the
U.S., edited by A. E. Clarke, L. Mamo, J. R. Fosket, J. R. Fishman, and J. K. Shim, 242262. Durham and London: Duke University Press.
Shuster, E. 1997. "Fifty Years Later: The Significance of the Nuremberg Code." New England
Journal of Medicine 337: 1436-1440.
Sunder Rajan, K. 2005. “Subjects of Speculation: Emergent Life Sciences and Market Logics in
the United States and India.” American Anthropologist 107: 19-39.
Sunder Rajan, K. 2006. Biocapital: The Constitution of Postgenomic Life. Durham and London:
Duke University Press.
Sunder Rajan, K. 2007. "Experimental Values: Indian Clinical Trials and Surplus Health." New
Left Review 45: 67-88.
—. 2012. "Pharmaceutical Crises and Questions of Value: Terrains and Logics of Global
Therapeutic Politics." The South Atlantic Quarterly 111: 321-346.
Timmermans, S. and M. Berg. 2003. The Gold Standard: The Challenge of Evidence-Based
Medicine and Standardization in Health Care. Philadelphia: Temple University Press.
Timmermans, S. and S. Epstein. 2010. "A World of Standards but not a Standard World: Toward

32

a Sociology of Standards and Standardization." Annual Review of Sociology 36: 69-89.
Whitmarsh, I. 2008. Biomedical Ambiguity: Race, Asthma, and the Contested Meaning of
Genetic Research in the Caribbean. Ithaca and London should you list both cities?:
Cornell University Press.
Williams, S. J., J. Gabe, and P. Davis. 2008. "The Sociology of Pharmaceuticals: Progress and
Prospects." Sociology of Health & Illness 30: 813-824.
Williams, S. J., P. Martin, and J. Gabe. 2011. "The Pharmaceuticalization of Society? A
Framework for Analysis." Sociology of Health & Illness 33: 710-725.
Williams, S. J., C. Seale, S. Boden, P. Lowe, and D. L. Steinberg. 2008. "Waking up to
Sleepiness: Modafinil, the Media and the Pharmaceuticalisation of Everyday/night Life."
Sociology of Health & Illness 30: 839-855.
Wolinsky, H. 2006. "The Battle of Helsinki " EMBO reports 7: 670-672.
WHO Drug Information v. 19, no. 3 2005, Access to Medicines.
U.S. Presidential Commission for the Study of Bioethical Issues, 2011. MORAL SCIENCE:
Protecting Participants in Human Subjects Research, Washington,
D.C.(http://www.bioethics.gov).
Zola, I. 1972. "Medicine as an Institution of Social Control." Sociological Review 20: 487-504.

33

Notes
1

According to the Pharmaceutical Research and Manufacturers of America (PHRMA),

only “one of every 10,000 potential medicines investigated by America’s research-based
pharmaceutical companies makes it through the research and development and is
approved for patient use by the United States Food and Drug Administration” and on
average it takes 15 years of research and development and more than $800 million for
each pharmaceutical that makes it to the market.
http://www.phrma.org/innovation/ PhRMA “Innovation” Retrieved Sept. 12, 2007
2

See Trials of War Criminals before the Nuremberg Military Tribunals under Control

Council Law No. 10", Vol. 2, pp. 181-182. Washington, D.C.: U.S. Government Printing
Office, 1949.
3

See the World Medical Association for the most current version of the Declaration

http://www.wma.net/en/10home/index.html
4

For example, in Mumbai, India, most of the subjects for clinical trials were recruited

from among unemployed textile workers who had lost their jobs after the collapse of the
textile industry in the 1980s and 1990s (Sunder Rajan 2005).
5

The Indian state has just begun to do this by issuing compulsory licenses for producing

generic versions of patented medicines (see Harris, NYT April 1, 2013).
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